¡Ya estamos en ! Descubre más
6.25 USD
-0.05
0.79%
Al cierre Actualizado 16 oct, 4:00 p.m. EDT
1 día
-0.79%
5 días
1.3%
1 mes
21.83%
3 meses
-6.16%
6 meses
-5.16%
En lo que va del año
-5.73%
1 año
-26.56%
5 años
-84.87%
10 años
-88.91%
 

Acerca de: Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.

Empleados: 753

Noticias

Positivo
Neutral
Negativo
Sentimiento 3 meses
Positivo 10%
Neutral 60%
Negativo 30%
Neutral
Business Wire
ayer
Inogen to Report Third Quarter 2026 Financial Results on November 5, 2026
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen to Report Third Quarter 2026 Financial Results on November 5, 2026.
Inogen to Report Third Quarter 2026 Financial Results on November 5, 2026
Neutral
Business Wire
hace 16 días
Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--INOGEN ANNOUNCES DIVESTITURE OF ITS U.S. OXYGEN RENTAL BUSINESS TO ROTECH.
Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech
Neutral
Zacks Investment Research
el mes pasado
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
INGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
Positivo
Zacks Investment Research
hace 2 meses
Should Investors Buy Inogen as Low Valuation Meets Execution Risk?
Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.
Should Investors Buy Inogen as Low Valuation Meets Execution Risk?
Negativo
Zacks Investment Research
hace 2 meses
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
Neutral
Zacks Investment Research
hace 2 meses
Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut
INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.
Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut
Neutral
Seeking Alpha
hace 2 meses
Inogen, Inc. (INGN) Q2 2026 Earnings Call Transcript
Inogen, Inc. (INGN) Q2 2026 Earnings Call Transcript
Inogen, Inc. (INGN) Q2 2026 Earnings Call Transcript
Negativo
MarketBeat
hace 2 meses
Inogen Q2 Earnings Call Highlights
Inogen NASDAQ: INGN reported second-quarter 2026 revenue of $95.1 million, up 3% from a year earlier, as international growth, portable oxygen concentrator demand and contributions from newer products offset continued pressure in its U.S. direct-to-consumer business.
Inogen Q2 Earnings Call Highlights
Negativo
Zacks Investment Research
hace 2 meses
Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates
Inogen (INGN) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.15 per share a year ago.
Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates
Neutral
Business Wire
hace 2 meses
Inogen Announces Second Quarter 2026 Financial Results
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Reported second quarter revenue of $95.1 million. Company raises full-year adjusted EBITDA guidance to approximately $4.0 million.
Inogen Announces Second Quarter 2026 Financial Results
Gráficos de precios implementados con Lightweight Charts™